Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LumiraDx Ltd LMDXF

Healthcare Medical Devices
LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless,... see more

Recent & Breaking News (OTCPK:LMDXF)

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

GlobeNewswire January 5, 2024

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

GlobeNewswire December 29, 2023

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

GlobeNewswire October 27, 2023

LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub

GlobeNewswire October 20, 2023

LumiraDx Reports Second Quarter 2023 Results

GlobeNewswire August 24, 2023

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

GlobeNewswire August 16, 2023

LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests

GlobeNewswire July 31, 2023

LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test

GlobeNewswire June 30, 2023

LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests

GlobeNewswire June 20, 2023

LumiraDx Reports First Quarter 2023 Results

GlobeNewswire May 16, 2023

LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16

GlobeNewswire May 9, 2023

LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire April 24, 2023

LumiraDx Announces Strategic Refocus and Cost Restructuring Program

GlobeNewswire April 6, 2023

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

GlobeNewswire March 21, 2023

LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21

GlobeNewswire March 14, 2023

LumiraDx to Present at Raymond James Institutional Investors Conference

GlobeNewswire March 3, 2023

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

GlobeNewswire February 17, 2023

LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay

GlobeNewswire February 6, 2023

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

GlobeNewswire January 31, 2023

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

GlobeNewswire January 31, 2023